Duchenne muscular dystrophy (DMD) is a progressive and ultimately fatal skeletal muscle disease. Currently, the most effective therapy is the administration of a subclass of glucocorticoids, most notably deflazacort. Although deflazacort treatment can attenuate DMD progression, extend ambulation, and maintain muscle strength, the mechanism of its action remains unknown. Prior observations have shown that activation of a JNK1-mediated signal transduction cascade contributes to the progression of the DMD phenotype, in part by phosphorylation and inhibition of a calcineurin sensitive NF-ATc1 transcription factor. Here, we observed that deflazacort treatment restored myocyte viability in muscle cells with constitutive activation of JNK1 and in dystrophic mdx mice. However, deflazacort treatment did not alter JNK1 activity itself, but rather led to an increase in the activity of the calcineurin phosphatase and an up-regulation of NF-ATc1-dependent gene expression. The prophylactic effect of deflazacort treatment was associated with increased expression of NF-ATc1 target genes such as the dystrophin homologue utrophin. Moreover, the muscle sparing effects of deflazacort were completely abolished when used in conjunction with the calcineurin inhibitor cyclosporine. Collectively, these results show that deflazacort attenuates loss of dystrophic myofiber integrity by up-regulating the activity of the phosphatase calcineurin, which in turn negates JNK1 inhibition of NF-ATc1-mediated phosphorylation and nuclear exclusion of NF-ATc1.
Although the genetic basis of DMD and the cellular localization of the dystrophin protein have been characterized, the precise mechanism that propagates the degeneration of dystrophic muscle remains obscure. The integrated position of dystrophin in the cytoskeletal architecture suggests a role in maintaining muscle fiber integrity. The dystrophin protein resides at the sarcolemma and forms cohesive interactions with cytoskeletal actin and a large protein scaffold, referred to as the dystrophin-glycoprotein complex (DGC), which contains transmembrane, as well as membraneassociated proteins, including dystroglycan and multiple members of the sarcoglycan family (5) . Accordingly, the absence of dystrophin leads to a disassembly of the entire DGC, forming the basis for an intrinsic mechanical defect. This structural defect is accelerated by the physiologic demands of an actively contracting muscle (5) . In addition, murine models of dystrophy such as the mdx mouse have demonstrated a linear relationship between peak force production and muscle fiber damage (6, 7) .
Dystrophic muscle degeneration may also be influenced by a nonmechanical response(s). This hypothesis is supported by the recent observation that mice harboring null mutations in components of the DGC, that is, γ-sarcoglycan gene, maintain normal resistance to mechanical strain in the skeletal musculature but continue to develop a progressive muscular dystrophy through an undefined chain of events (8, 9) . The nonmechanical hypothesis is further strengthened by the observation that the evolving cellular milieu of a dystrophic muscle fiber leads to the activation of apoptosis/programmed cell death (10, 11) . Invoking a hypothesis that apoptosis and/or nonmechanical mechanisms are significant contributing factors for dystrophic pathology implies that the dystrophic milieu triggers activation of a deleterious signal transduction pathway. Consistent with this concept, the JNK1 effector kinase has been reported to be associated with the DGC (12) and to be constitutively activated in dystrophic muscle (13, 14) . Within this context, JNK1 activation results in the targeted phosphorylation of NF-ATc1, leading to nuclear export of this vital striated muscle transcription factor with loss of appropriate target gene activation (14) . Accordingly, blockade of this kinase using a JNK1-specific scaffold protein dramatically attenuated the loss in myofiber integrity associated with dystrophy progression (14) . This observation would also suggest that pharmacologic manipulation of this pathway may provide an amenable route to treat or subdue dystrophic myofiber pathogenesis.
Currently, the only amenable disease intervention available to DMD patients is through the administration of a subclass of glucocorticoids, specifically prednisone and deflazacort. A potential clinical benefit for these compounds was discovered with single case/small group observations of prednisone-treated DMD patients, which resulted in normalization of muscle biochemical profiles (15) . These initial studies were followed by extensive randomized clinical trials of prednisone use in DMD patients, demonstrating that prednisone improved muscle strength and pulmonary function, as well as extending ambulation by up to two years (16, 17) , leading to the widespread use of prednisone as a prophylactic treatment for DMD. Despite the success of prednisone, a number of side effects have limited its usefulness. As such, the oxazoline derivative of prednisone (deflazacort) has emerged as an equally effective treatment for DMD, owing to the diminished severity of side effects (18) (19) (20) (21) . Despite these observations and the results of numerous studies demonstrating the potent phenotypic correction for glucocorticoid-treated dystrophic muscle/myofibers, the cellular or molecular mode of action for these compounds remains obscure (22) .
Glucocorticoids are routinely and effectively used to treat chronic inflammatory diseases (23) . There is increasing evidence that the inflammatory response seen in a variety of tissues is partially modulated by the activation of JNK1 (24, 25) . Studies have reported a decrease in JNK1 activation associated with dexamethasone treatment of HeLa cells and human monocytes, providing a potential conduit for their action (26, 27) . Here, we report that the glucocorticoid deflazacort counteracts the dystrophic effects of JNK1 activation through an indirect mechanism. Specifically, deflazacort treatment leads to increased activation of the calmodulin-dependent phosphatase, calcineurin leading to activation of NF-ATc1 dependent gene expression and thereby attenuation of the dystrophic phenotype.
MATERIALS AND METHODS

Cell culture
C2C12 cells expressing MKK7 were as described previously (14) . Before treatment with inhibitors and/or drugs, cells (70% confluent) were switched to differentiation (serum-deprived) medium (2% horse serum), and allowed to acclimatize for 6 to 24 h. Deflazacort, prednisone (Sigma-Aldrich, St. Louis, MO), IGF-1 (Sigma-Aldrich), RU486 (Sigma-Aldrich) or Cyclosporin A (Sigma-Aldrich) were added in the combinations and concentrations required directly to the medium and replenished every 24 h. Cells were fixed and used for immunostaining or calcineurin activity assays as described below.
Histology and immunostaining
Tissues from mdx mice (28) were excised and rinsed in ice cold TBS before embedding in OCT medium (Fisher Scientific, Pittsburgh, PA) for frozen sectioning. Tissues not used immediately were flash frozen in liquid nitrogen and stored at −80°C until use. Five-to ten-µm sections were mounted onto glass slides and either stored at −80°C or used immediately for immunohistochemistry. Detection of sarcolemmal utrophin and utrophin A were conducted as described (29) . Briefly, TA cross sections were incubated with H-300 polyclonal antibodies recognizing the C terminus of utrophin (Santa-Cruz Biotechnology, Inc., Santa Cruz, CA), or with previously characterized antibodies generated in our laboratory, specific for residues in the N-termini of utrophin A (29) . For visualization of muscle structure, sections were stained with haemotoxylin and eosin. The percentage of fibers with centrally located myonuclei was calculated as the percentage of fibers exhibiting a centrally localized nuclei compared with the total number of fibers in each section. To determine relative fiber size variability, the average deviation form the mean was divided by the mean value for fiber surface area from individual sections. All histologic and morphologic assessments of tissue sections were performed in a blinded fashion, that is, the identity of the samples as related to treatment groups remained unknown until all data analysis was complete.
C2C12/MKK7 cells stained for myosin heavy chain (MHC) expression were first fixed in 70% ethanol for 10 min, rinsed in PBS and then blocked for 1 h in 5% milk protein at room temperature. Cells were rinsed in PBS, MF-20 mouse antiserum (Developmental Hybridoma Bank) was added at a concentration of 1:50 in PBS + 5% milk protein and incubated for 1 h at room temperature. After rinsing (3 × 5 min in PBS), HRP-conjugated goat anti-mouse secondary antibody was applied at 1:1000 in 50 mM Tris-HCl pH 7.6 with 5% milk protein and incubated for 30 min at room temperature. Staining was visualized with 3′,3′-diaminobenzidine (Sigma). Staining was visually monitored and stopped by washing in PBS. Stained cells were stored at 4°C in PBS containing 0.1% thimerasol. The percentage of cells expressing MHC was quantified by measuring the percentage of cells expressing MHC in random fields of view chosen for statistical analysis. C2C12 or C2C12/MKK7 cells cultured in chamber slides (Fisher Scientific) were fixed in 70% ethanol, treated with permeabilization buffer (Cellomics, Pittsburgh, PA) and immunostained for NF-ATc1 using a monoclonal antibody (Affinity Bioreagents, Golden, CO), and visualized with a GFP-conjugated secondary antibody (Cellomics). All digital photography was performed using a Zeiss camera.
Deflazacort/cyclosporine A injections
Mdx pups (3 weeks) were injected interperitoneally with deflazacort (1 mg/kg body weight) and/or cyclosporin A (25 mg/kg body weight) resuspended in sterile saline every 2 days for up to 3 weeks. Sham-injected controls received saline alone. Mice were then killed and tissues removed for analysis.
Protein lysates and Western blotting
Cell lysates (75 µg/well) were run on SDS-polyacrylamide gels (10%), blotted onto Immobilon-P membrane (Millipore, Bedford, MA) and immunostained for phosphorylated JNK-1 using a polyclonal antibody (Promega, Madison, WI) at 1:5000 in TBST + 1% BSA overnight (14) . Membranes were washed in TBST and then incubated with anti-rabbit secondary antibody conjugated to HRP (Bio-Rad Laboratories, Hercules, CA) in TBST + 1% BSA for 1 h at room temperature. Bands were visualized using the ECL detection kit (Amersham-Pharmacia Biotech, Inc., Piscataway, NJ). Analyses for p38 were performed using a rabbit polyclonal primary (Santa Cruz Biotechnology) and goat anti-rabbit secondary antibodies (Bio-Rad). NF-ATc1 detection was achieved as described above.
Reporter assays
C2C12 or C2C12/MKK7 cells were transfected with either IL-2, IL-4, or utrophin promoter constructs and control reporter plasmids using Lipofectamine Plus (Invitrogen, Carlsbad, CA). Following transfection, cells were fed with differentiation medium and treated with 10 µg/ml of deflazacort (DFZ) for 48 hrs. Cells were scrapped into 200 µl 1× Reporter Lysis Buffer (Promega, Madison, WI), stored at −0 °C and thawed at room temperature in a water bath. Debris was spun down, supernatant transferred to a fresh tube, and assayed for β-galactosidase (β-gal) and luciferase activity. β-gal activity was quantified using 2-nitrophenyl β-Dgalactopyranoside (Sigma) as substrate. Luciferase activity was quantified using the Luciferase Assay System (Promega). The IL-2 (30) and IL-4 (31) promoter reporter constructs modulating luciferase expression, gifts from Anjana Roa and Steven Georas, respectively, were cotransfected with a control plasmid expressing β-gal driven by a CMV promoter. The utrophin promoter construct driving β-gal expression (29) was cotransfected with a control plasmid expressing luciferase under the control of a CMV promoter.
RNA extraction and quantitative RT-PCR
Total RNA was extracted using TriPure (Boehringer Mannheim) as recommended by the manufacturer. Quantitative RT-PCR was carried out to determine the relative abundance of total utrophin (both A and B together), utrophin A and utrophin B using primers that selectively amplify total utrophin, utrophin A, utrophin B, and S12 rRNA (32, 29) . Cycling conditions were optimized for all targets. In all these assays, negative controls consisted of RT mixtures in which total RNA was replaced with RNase-free water. PCR products were first visualized on 1% agarose gels containing ethidium bromide (Sigma-Aldrich). For quantitative measurements, PCR products were separated and visualized on agarose gels containing the fluorescent dye Vistra Green (Amersham). The labeling intensity of the PCR product, which is linearly related to the abundance of cDNAs, was quantified using a Storm PhosphorImager (Molecular Dynamics, Montreal, QC, Canada). Values obtained for utrophin, utrophin A, and utrophin B were standardized relative to the amount of S12 rRNA present in the same sample. For all quantitative measurements, PCR experiments were performed during the linear range of amplification as described and shown in detail in our earlier work (33, 34) .
Calcineurin activity assay
Calcineurin activity assays were performed on indicated cell lysates using the calcineurin activity assay kit (Calbiochem, kit no. 207007).
RESULTS
Deflazacort attenuates JNK1-dependent differentiated myocyte loss in vitro
In prior studies, we have demonstrated that constitutive activation of JNK1 contributes to the development of the dystrophic phenotype in skeletal muscle and limiting the activity of this kinase in vivo limits the disease progression (14) . Therefore, the phenotypic rescue of dystrophy following glucocorticoid/deflazacort (DFZ) administration may result from a repression or limitation of JNK1 activity. To test this supposition, we exposed C2C12 skeletal muscle myoblasts stably transfected with the JNK1 activating kinase, MKK7 (C2C12/MKK7 cells) to a DFZ treatment protocol. Initial studies were undertaken to determine the potential toxicity of DFZ on C2C12/MKK7 myoblasts and to determine working concentrations. MKK7 myoblasts cultured in medium containing 10 µg/ml of DFZ for 7 days appeared to be healthy and robust and exhibited the multinucleate phenotype indicative of myotube fusion (Table 1) . However, as DFZ levels increased, toxicity of the drug increased, so that at 50 µg/ml or greater, cells become vacuolated and necrotic. Concentrations of less than 10 µg/ml were well tolerated, but did not provide measurable phenotypic rescue. Subsequently, a nontoxic dosing regime of 10 µg/ml DFZ was used to assess the viability of differentiated MKK7 myocytes.
As previously observed, overexpression of MKK7 leads to elevated JNK1 activity (Fig. 1A ) and a loss of C2C12 differentiated myocyte integrity within 5 days of low serum induction of differentiation ( Fig. 1B and 1C ). The addition of DFZ to the medium (10 µg/ml) increased myosin heavy chain (MHC) expression substantially by three days and maintained differentiated myocyte viability and MHC expression at 5 days ( Fig. 1D and 1E ) and at culture times of 1 week or greater (data not shown). For comparison, cells were also subject to IGF-1 treatment. IGF-1 has been well established as an anabolic growth catalyst in muscle cell lineages and musclespecific overexpression of IGF-1 in the mdx dystrophic mouse model leads to increased muscle mass, regenerative capacity, and strength, as well as decreased fibrosis (35, 36) . C2C12/MKK7 myoblasts cultured in low serum conditions with 3 ng/ml of IGF-1, displayed noticeable rescue of the atrophic phenotype ( Fig. 1F and 1G ). However, this differentiated myocyte rescue was not as robust as that provided by DFZ treatment (see below). In addition, cells grown in the presence of both IGF-1 and DFZ did not display any significant differences in differentiated myocyte viability when compared with cells treated with DFZ alone (data not shown).
Although not conclusive, this observation suggested that IGF-1 and DFZ circumvented the deleterious effects of JNK1 activity through the same cellular mechanism. As a first step in addressing the probable cellular target, we examined the ability of DFZ to alter JNK1 activity. Interestingly, C2C12/MKK7 cells treated with a range of DFZ concentrations did not display attenuation in JNK1 phosphorylation (Fig. 1H) , suggesting that the mechanism of action for this drug does not appear to be via direct perturbation of the JNK1 kinase.
Deflazacort treatment of myoblast/myotube cultures activates the phosphatase calcineurin
The ability of DFZ to limit the atrophic effect of JNK1, yet not perturb JNK1 activity appeared paradoxical. Nevertheless, such an apparent contradiction could be explained if one considers the possibility that DFZ may limit the dystrophic phenotype by restoration of activity/function of a protein, which itself is negatively regulated by JNK1. Certainly, the calcium calmodulindependent phosphatase calcineurin may represent such a candidate protein. Calcineurindependent signaling has been demonstrated to regulate both cardiac and skeletal muscle hypertrophy (37, 38) , and calcineurin specifically has been shown to be a convenor of the IGF signal for inducing skeletal myofiber hypertrophy (39) . Therefore, we examined the effect of DFZ on calcineurin activity in wild-type and C2C12/MKK7 myoblasts. In a series of experiments, C2C12/MKK7 cells were treated with either prednisone (10 µg/ml; the parent compound from which DFZ is derived), DFZ (10 µg/ml), IGF-1 (3 ng/ml), or a combination of DFZ and the calcineurin inhibitor cyclosporin A (CsA) and compared with untreated controls. As previously observed, untreated MKK7 myoblast cultures exhibited low levels of differentiated myocyte viability and MF20 staining. Cultures subjected to medium containing prednisone or IGF-1 displayed significant improvement in both indices (P<0.05), while DFZ treatment provided an even greater sparing effect (P<0.05) ( Fig. 2A) . Of significance, cultures subjected to a cocktail containing both DFZ and CsA resulted in a dramatic decrease in differentiated myocyte viability and MHC expression, suggesting that CsA inhibition of calcineurin was sufficient to block any rescue normally associated with DFZ.
To complement these observations, we then measured calcineurin activity directly. To establish a baseline for the assay, differentiating wild-type C2C12 myoblasts were measured to determine calcineurin activity. Similar to prior observations, calcineurin activity steadily increased over a 3-day time period following low-serum induction of differentiation (40), moreover, the addition of DFZ to the medium led to a noticeable increase in calcineurin activity levels over those measured in untreated wild-type C2C12 cells (Fig. 2B) . We then measured calcineurin activity in C2C12/MKK7 cultures over the same time course. In addition to DFZ, cultures were also treated with DFZ plus RU486, an inhibitor of glucocorticoid receptor activity, and DFZ plus CsA. Untreated cultures showed little evidence of calcineurin activity over a 3-day period (Fig. 2C) . The addition of DFZ to the medium produced a significant up-regulation of calcineurin activity, the levels remaining constant over the time course measured. Cultures exposed to DFZ and CsA showed a decrease in calcineurin activity, as did the combination of DFZ plus RU486. Calcineurin levels remained steady over time for both treatment regimens, although at 72 h, phosphatase activity was undetectable in cells treated with both DFZ and RU486. This may reflect a change in the state or number of glucocorticoid receptors produced after prolonged exposure to the inhibitor and its unusually long half-life (41) .
One caveat to consider with these measurements is the low to undetectable baseline calcineurin activity in C2C12/MKK7 cultures. A plausible explanation for these results relates to the phenotype of the cells within the cultures. For example, myotube viability rapidly declines in the low-serum C2C12/MKK7 cultures, such that the majority of cells remaining are nondifferentiated single myoblasts, a cell type with inherently reduced calcineurin activity (40) . As the protein lysates used in the activity assay were derived from the entire cell population, the calcineurin activity assay will not discriminate between responding and nonresponding cell types, the end result being that the phosphatase signal may be significantly diluted. Despite this technical limitation, it is clear that DFZ treatment increases the activity of the calcineurin enzyme.
Deflazacort stimulates NF-ATc1 nuclear translocation and transcriptional activity in vitro
Having established that DFZ treatment of C2C12/MKK7 cells induced calcineurin activity, we next examined the effect of DFZ on a probable calcineurin target, the NF-ATc1 transcription factor. The nuclear localization, and hence transcriptional activity of the NF-AT transcription factor family, is dependent on dephosphorylation, mediated by the calcineurin phosphatase (42) . We have observed in previous studies that elevated JNK1 activity in a dystrophic muscle leads to a direct interaction with and phosphorylation of NF-ATc1. In turn, this JNK1-mediated phosphorylation leads to cytoplasmic accumulation of NF-ATc1 (14) . Therefore, to address the role of NF-ATc1 as a probable DFZ/glucocorticoid target, wild-type C2C12 and MKK7 myoblast/myotubes were subjected to immunostaining with anti-NF-ATc1 following DFZ exposure. DFZ-treated C2C12/MKK7 myoblasts in serum-depleted medium displayed a uniform NF-ATc1 localization to the nuclear compartment (Fig. 3A-C) . As a control for NF-ATc1 localization, we used the drug thapsigargin. Thapsigargin is a cell-permeable sesquiterpene lactone that inhibits microsomal-associated Ca 2+ -ATPase. As such, calcium sequestration is blocked, cytosolic calcium levels increase activating the calmodulin/calcineurin cascade. When cells are treated with thapsigargin, there was a rapid (within 4 h) mobilization of NF-ATc1 to the nucleus, a pattern that is similar to NF-ATc1 distribution observed in wild-type myoblasts during differentiation (data not shown). However, in the absence of DFZ, C2C12/MKK7 myoblast/myotube cultures revealed a dramatic alteration in NF-ATc1 localization, as evidenced by a substantial reduction of NF-ATc1 in the nuclear compartment (Fig. 3D-F) . In addition, Western blot analyses of subcellular fractionated myoblasts (cytoplasmic vs. nuclear fractions) revealed a similar NF-ATc1 distribution, that is, CsA retained NF-ATc1 in the cytoplasm, thapsigargin treatment induced nuclear relocation of NF-ATc1 in wild-type myoblasts (Fig. 3G) , and DFZ treatment of C2C12/MKK7 myoblasts revealed a nuclear enrichment of unphosphorylated NF-ATc1 (Fig. 3H) . The NF-ATc1 antibodies used for the Western blot analysis typically detect 3 NF-ATc1 isoforms that migrate between ~82 kD and 125 kD. These bands represent variable forms of post-translationally modified NF-ATc1, specifically variable phosphorylation of the protein, with the upper most band representing phospho-epitopes and the lower most species representing de-phosphorylated epitopes (39, 40) . Myoblast/myotube cultures were also examined for alterations in other NF-AT proteins following deflazacort treatment. For example, although other NF-AT proteins were expressed at moderate levels in the muscle cells (i.e., NF-AT1, etc.), the pattern of immunostaining revealed a much-reduced nuclear localization compared with NF-ATc1 (data not shown).
Given that DFZ exposure leads to restoration of nuclear NF-ATc1, one logical course of action will be to identify the NF-ATc1-dependent transcriptional responses that ultimately lead to phenotypic correction. One probable candidate is the dystrophin like protein utrophin. Upregulation of utrophin expression has been demonstrated to provide a functional correction for dystrophin deficiency (43) and the additional absence of utrophin has been shown to accelerate dystrophy pathogenesis (44, 45) . In addition, recent studies from our laboratory have shown that the utrophin promoter is responsive to a calcineurin/NF-ATc1 signal (29) . To address the relevance of utrophin expression in this context, we measured utrophin promoter activity in utrophin-reporter construct transfected wild-type and MKK7/C2C12 myoblasts. Following DFZ treatment, we observed a significant increase in utrophin transcriptional activity in both wildtype and MKK7/C2C12 myocytes (Fig. 3I) . The DFZ induced transcriptional induction of utrophin was also concurrent to increased expression of the protein itself (data not shown). Although the increased utrophin expression in this model likely provides a measurable benefit, DFZ treatment may engage other transcriptional responses that limit the atrophy of MKK7/C2C12 cells. In this regard, we chose to examine the activity of the interleukin 4 (IL-4) promoter, as IL-4 appears to be an NF-AT induced cytokine that increases myofiber size through a myoblast recruitment strategy (46) . As with the utrophin promoter, DFZ treatment led to a robust increase in IL-4 promoter activity in reporter transfected wild-type and MKK7/C2C12 myocytes (Fig. 3J) . Interestingly, other NF-AT dependent promoters such as IL-2 were not as responsive to DFZ treatment in similarly transfected myoblasts (Fig. 3K ). These observations suggest that DFZ activation of calcineurin may lead to selective or partial targeting of the NF-AT protein family to specific NF-AT proteins that do not transactivate the IL-2 promoter as effectively as other NF-AT sensitive promoters. In addition, both utrophin and IL4 are well characterized skeletal muscle responsive genes, while IL-2 is not typically known to be a robustly expressed cytokine in skeletal muscle. Together, these data indicate that DFZ counteracts the atrophic effects of JNK1 by activating the calcineurin phosphatase and restoring the nuclear localization and transcription activity of NF-ATc1.
Deflazacort treatment limits dystrophic myofiber degeneration in vivo by activation of the calcineurin pathway
Previous studies using the dystrophic mdx mouse model have shown that administration of DFZ can reduce the severity of the dystrophic phenotype, yet the mechanistic basis of this rescue remains obscure (47, 48). As such, we extended our analysis to examine the effects of DFZ treatment on dystrophic mouse skeletal muscle using the mdx strain, and whether activation of the calcineurin/NF-AT pathway mediated the phenotypic rescue that is typically observed with glucocorticoid treatment. To this end, 3-week-old mdx mice were subject to a variable treatment regime with vehicle (saline), DFZ, or DFZ and cyclosporine injections for 1 week. As expected, DFZ treatment alone largely inhibited the degenerative changes in the mdx skeletal muscle, as evidenced by a twofold reduction in the number of centrally located myonuclei (hallmark of regenerating fibers) (Fig. 4A, B, and D) , a reduction in the fiber size variability (Fig. 4E) , maintaining a higher percentage of larger-diameter myofibers and reduced evidence of degenerating fibers with cellular infiltrates (Fig. 4A, B) . Interestingly, when mice were concurrently treated with cyclosporine and DFZ, the phenotypic rescue of the myofibers was largely abolished, that is, with more visible fiber damage, increased central nucleation, and increased fiber size variability compared with DFZ alone (Fig. 4B-4E) . Moreover, the beneficial effects of DFZ could be observed at the end of the first week of treatment and was also maintained for longer treatment regimes of 3−4 weeks. Not surprisingly, cellular infiltration was curbed with the combinatorial treatment of DFZ and cyclosporine. In addition to these morphologic effects, DFZ treatment also led to a restoration of NF-ATc1 to the myonuclei of dystrophic skeletal muscle (data not shown). Taken together, these results reinforce the concept that DFZ acts directly on the dystrophic myofiber to limit disease progression.
Deflazacort treatment of dystrophic mice leads to a calcineurin-mediated up-regulation of utrophin expression
Both in vitro and in vivo analyses suggest that DFZ treatment leads to a relocalization of NFATc1 to the myonuclei with a concurrent phenotypic rescue of dystrophic pathology. Moreover, this in vivo phenotypic rescue was consistent with maintaining myofiber integrity and suggests that this rescue is derived from enhanced expression of a NF-ATc1 target gene that acts as a myofiber protective factor. Therefore, the expression of utrophin was monitored in dystrophic mdx mice subject to saline, DFZ, or DFZ and cyclosporine treatments. Within 7−8 days of initiating DFZ treatment, utrophin transcript expression increased approximately twofold, the increase being most prominent for utrophin A transcripts (Fig. 5A ). This DFZ-dependent increase in utrophin expression was eliminated when combined with cyclosporine treatment (Fig. 5A) . The DFZ-stimulated increase in utrophin transcripts were mirrored by a robust increase in the expression and sarcolemmal localization of utrophin protein (Fig. 5B) , a response also readily inhibited with concurrent cyclosporine exposure (Fig. 5B) . Together, these data suggest that the DFZ treatment limits dystrophic pathology by up-regulating utrophin expression via an increase in calcineurin activity and thereby maintaining the health of the existing myofiber population.
DISCUSSION
Following the discovery of the dystrophin gene in 1987, treatment of muscular dystrophy has focused primarily on using gene therapy approaches to redress the paucity of dystrophin protein and thereby restore myofiber integrity. Although this strategy has been pursued by many research teams, the elucidation of the mechanisms that underlie glucocorticoid relief of dystrophic progression have been largely ignored. In this paper, we have begun to unravel the intracellular signaling conduits that are modulated by the action of these powerful drugs. For example, the inappropriate activation of JNK1 appears to be responsible, at least in part, for the generation of the dystrophic phenotype (14) . This intriguing finding led us to investigate whether the therapeutic benefits derived from glucocorticoid treatment of dystrophy might have their basis in the modulation of the JNK1-signaling conduit. Indeed, our research suggests that DFZ administration counteracts the negative signal influence of JNK-1 activity, although this effect does not involve manipulation of the JNK-1 kinase itself. Rather, DFZ treatment leads to the activation of calcineurin, which in turn provides the mechanism to dephosphorylate NF-ATc1 (a JNK-1-targeted protein), leading to relocation of NF-ATc1 and restoration of appropriate muscle gene expression.
Many assumptions have been made in regard to glucocorticoid treatment of dystrophy, common among these opinions are that glucocorticoids act to alleviate dystrophic pathology primarily through immunosuppression and reducing attendant inflammation. Although our data do not confirm or deny this supposition, we do observe that a primary target of DFZ treatment appears to be skeletal muscle itself. For example, DFZ treatment was capable of curtailing the atrophic effects of the JNK1 signal cascade in skeletal muscle culture models. Second, the observed increase in expression of the dystrophin homologue utrophin, strongly argues in favor of the "myofiber sparing" hypothesis. Undoubtedly, myofiber protection is a key outcome of DFZ treatment, yet other mechanisms may contribute to the efficacy of the drug. For example, we have observed that the NF-AT responsive IL-4 promoter is activated during DFZ treatment of muscle cell cultures, and this activation pattern is as robust as that observed for utrophin. Interestingly, IL-4 itself has been shown to promote the fusion of myoblasts to pre-existing myotubes (46) . Although we have not directly tested the requirement of IL-4 in the current study, it is reasonable to suggest that the full range of DFZ effects may include an IL-4-mediated increase in myoblast fusion during the ongoing degeneration and regeneration of the dystrophic muscle life cycle.
The present study has shown that DFZ treatment provides relief of dystrophy symptoms in a manner similar to IGF-1 treatment (36) . Both DFZ and IGF-1 appear to be potent inductive cues for stimulating calcineurin activity. However, it is probable that DFZ and IGF-1 stimulate calcineurin activity through distinct precipitating events. IGF-1 functions via a specific receptor that can provide access to at least two different signaling cascades, including the phosphatidylinositol (PI) and MAP kinase pathways (49). DFZ on the other hand, appears to operate via interaction with glucocorticoid receptors (GR). Indeed, the differentiated myocyte rescue associated with DFZ treatment of JNK1 active C2C12 cultures was completely blocked when medium was supplemented with the corticosteroid inhibitor RU486. Cells treated with RU486 remain receptive to exogenous IGF-1 but not to glucocorticoids, again indicating that the initial stimulus provided by both IGF-1 and DFZ is associated with different access points. Despite a probable disparity in the signal cascades for IGF and DFZ, the immediate upstream events leading to calcineurin activation with IGF and DFZ treatment are likely similar. For example, both IGF-1 and glucocorticoids alter cytosolic calcium concentrations, which in itself is a stimulus for a calcium sensitive phosphatase such as calcineurin. IGF-1 exposure leads to increased Ca 2+ flux via up-regulation of L-type calcium channel gene expression (50) . Similarly, glucocorticoid treatment has been demonstrated to alter Ca 2+ flux in skeletal muscle cells while enhancing the development of myofiber formation (51) . Therefore, DFZ may act in part to redress cytosolic Ca 2+ shifts normally associated with dystrophy or may activate a downstream effector protein not involved with calcium flux directly.
The beneficial effects imparted by DFZ administration rapidly disappear following drug withdrawal, suggesting the presence of a DFZ-sensitive mechanism within the dystrophic muscle environment, that is, calcineurin activity. As such, gene therapy approaches targeting the activation of this phosphatase or pathway components may be better suited to alleviating the symptomology of dystrophy than those focused on replacing dystrophin itself. For example, transgenic overexpression of calcineurin has been demonstrated to rescue the dystrophic muscle pathology that is normally associated with the mdx strain (52) . However, given that calcineurin is an enzyme, a more reasonable course for therapy development may involve classic pharmacologic approaches, such as the design and utilization of small molecules/drugs to increase calcineurin activity. Moreover, similar targeting of JNK1 must also be considered. For example, in addition to targeting NF-ATc1, elevated JNK1 activity also leads to increased expression of β-amyloid precursor protein (14) , which itself has been linked to a form of skeletal muscle pathology (53) . In addition, it appears that JNK1 activity is one of many signal perturbations, some or all of which may represent valid therapeutic targets (12, (54) (55) (56) . Nevertheless, the observations of the current study indicate that an effective treatment for dystrophy patients may finally be realized with the use of combinatorial pharmacologic strategies and rationale drug design, selectively targeting an increase in calcineurin activity, and/or inhibiting JNK1 activity. blot analyses of C2C12/MKK7 myoblasts using antiphosphospecific JNK1 indicate that low, medium (mid), and high MKK7 expression is directly correlated to the activation status of JNK1. B) C2C12/MKK7 myoblasts initially exhibit normal differentiation profiles, staining positive for MHC after 3 days in serum-depleted medium. C) By 5 days, the number of MHC-positive myotubes has decreased dramatically, and cells become pycnotic and vacuolized. D, E) The addition of DFZ to the medium (10 µg/ml) results in a restoration of differentiated myocyte integrity at 3 and 5 days. F, G) The addition of IGF-1 to the medium (3 ng/ml) also maintained differentiated myocyte viability at 3 and 5 days, although not to the same degree as DFZ. H) The addition of DFZ (range of concentrations) does not alter levels of phospho-JNK (JNK p54 or JNK p46) in C2C12/MKK7 myoblasts. Western blot analyses of DFZ-treated C2C12/MKK7 myoblast lysates using antiphosphospecific JNK1 revealed no change in JNK1 phosphorylation (anti-p38α was used as a loading control). Fig. 2 (cont)   Figure 2 . Deflazacort (DFZ) can induce calcineurin (CnA) activation in vitro. A) C2C12/MKK7 cultures have few myosin heavy chain (MHC) positive myoblast/myocytes following 72 h in serum deprived medium (~5%). The addition of the glucocorticoid prednisone to the medium increases this number to 12% (P<0.05). DFZ treated cultures exhibit a further increase in differentiated myocyte viability as evidenced by the 20% MHC positive index. IGF-1, a known mobilizer of calcium, maintained differentiated myocyte viability to levels approximating that of prednisone treated cells. The addition of both DFZ and the CnA inhibitor cyclosporin A (CsA) to the medium reduced differentiated myocyte viability to baseline levels, suggesting a direct link between the drug and CnA activation. B) In wild-type C2C12 myoblasts, CnA activity (as measured by phosphate release) increases following low serum induction of differentiation (blue). The addition of DFZ to the medium has little effect on CnA activity (red), suggesting that the glucocorticoid is unable to further activate CnA above that seen in normally differentiating cells. C) CnA activity assay of C2C12/MKK7 cultures treated with DFZ alone or in combination with RU486 or CsA. The addition of DFZ resulted in a significant increase in free phosphate in the assay, a measure of CnA activity. The addition of DFZ and RU486 (10 −8 M), a potent glucocorticoid receptor antagonist, produced a significant decrease in phosphate release, indicating a drop in CnA activity.
The result further suggests that by antagonizing receptor ligand interaction, DFZ cannot mediate CnA activation. Similarly, DFZ administered with CsA (1.0 ng/ml) also produced a decrease in CnA activity. All data are reported as ± 
